Reactome | IFNAR2:JAK1:STAT2 binds JAK1,2 inhibitors

IFNAR2:JAK1:STAT2 binds JAK1,2 inhibitors

Stable Identifier

R-HSA-9678935

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol, plasma membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

IFNAR2:JAK1:STAT2 binds JAK1,2 inhibitors

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. JAK1 binds to and is inhibited by several small molecule drugs (Clark et al. 2014, Fridman et al. 2010). Drugs that inhibit these kinases such as baricitinib, tofacitinib, delgocitinib and ruxolitinib are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Peterson et al. 2020, Richardson et al. 2020).

Literature References

PubMed ID	Title	Journal	Year
32511913	Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders Doi, S, Shiozaki, M, Orita, T, Yamamoto, H, Hase, Y, Hara, Y, Yamanaka, H, Ogawa, Y, Oki, C, Noji, S, Obika, S, Maeda, K, Kimoto, Y, Hashimoto, H, Negoro, T, Adachi, T, Inoue, M, Miura, T, Hori, A, Tanimoto, A	J Med Chem	2020
24417533	Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases Clark, JD, Telliez, JB, Flanagan, ME	J. Med. Chem.	2014
20130243	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Li, J, Quintás-Cardama, A, Rupar, M, Manshouri, T, Kantarjian, H, Burn, T, Wen, X, Lo, Y, Liu, P, Verstovsek, S, Covington, M, Scherle, PA, Kelley, J, Waeltz, P, Caulder, E, Shepard, S, Vaddi, K, Fridman, JS, Haley, P, Li, Y, Rodgers, JD	Blood	2010
20363976	Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050 Favata, MF, Shi, J, Yeleswaram, S, Li, J, Metcalf, B, Wen, X, Scherle, PA, Thomas, B, McGee, R, Collins, R, Newton, RC, Burn, TC, Covington, MB, Friedman, SM, Shepard, S, Haley, PJ, Vaddi, K, Hollis, G, Fridman, JS, Li, Y, Rodgers, JD, Collier, P	J. Immunol.	2010